Background: Health Technology Assessment (HTA) is a crucial tool for evaluating the worth and roles of health technologies, and providing evidence-based guidance for their adoption and use. Artificial intelligence (AI) can enhance HTA processes by improving data collection, analysis, and decision-making. This study aims to explore the opportunities and challenges of utilizing artificial intelligence (AI) in health technology assessment (HTA), with a specific focus on economic dimensions. By leveraging AI's capabilities, this research examines how innovative tools and methods can optimize economic evaluation frameworks and enhance decision-making processes within the HTA context. Methods: This study adopted Arksey and O'Malley's scoping review framework and conducted a systematic search in PubMed, Scopus, and Web of Science databases. It examined the benefits and challenges of AI integration into HTA, with a focus on economic dimensions. Findings: AI significantly enhances HTA outcomes by driving methodological advancements, improving utility, and fostering healthcare innovation. It enables comprehensive assessments through robust data systems and databases. However, ethical considerations such as biases, transparency, and accountability emphasize the need for deliberate planning and policymaking to ensure responsible integration within the HTA framework. Conclusion: AI applications in HTA have significant potential to enhance health outcomes and decision-making processes. However, the development of robust data management strategies and regulatory frameworks is essential to ensure effective and ethical implementation. Future research should prioritize the establishment of comprehensive frameworks for AI integration, fostering collaboration among stakeholders, and improving data quality and accessibility on an ongoing basis.

This study attempted to review the evidence for or against the effectiveness of mobile health (m-health) interventions on health outcomes improvement and/or gestational diabetes mellitus (GDM) management. PubMed, Web of Science, Scopus, and Embase databases were searched from 2000 to 10 July 2018 to find studies investigating the effect of m-health on GDM management. After removing duplications, a total of 27 articles met our defined inclusion criteria. m-health interventions were implemented by smartphone, without referring to its type, in 26% (7/27) of selected studies, short message service (SMS) in 14.9% (4/27), mobile-based applications in 33.3% (9/27), telemedicine-based on smartphones in 18.5% (5/27), and SMS reminder system in 7.1% (2/27). Most of the included studies (n=23) supported the effectiveness of m-health interventions on GDM management and 14.3% (n=4) reported no association between m-health interventions and pregnancy outcomes. Based on our findings, m-health interventions could enhance GDM patients' pregnancy outcomes. A majority of the included studies suggested positive outcomes. M-health can be one of the most prominent technologies for the management of GDM.

AIM: To review all of epidemiological aspects of non-alcoholic fatty liver disease (NAFLD) and also prevent this disease is examined. METHODS: We conducted a systematic review according to the PRISMA guidelines. All searches for writing this review is based on the papers was found in PubMed (MEDLINE), Cochrane database and Scopus in August and September 2014 for topic of NAFLD in Asia and the way of prevention of this disease, with no language limitations. All relevant articles were accessed in full text and all relevant materials was evaluated and reviewed. RESULTS: NAFLD is the most common liver disorder in worldwide, with an estimated with 20%-30% prevalence in Western countries and 2%-4% worldwide. The prevalence of NAFLD in Asia, depending on location (urban vs rural), gender, ethnicity, and age is variable between 15%-20%. According to the many studies in the world, the relationship between NAFLD, obesity, diabetes mellitus, and metabolic syndrome (MS) is quiet obvious. Prevalence of NAFLD in Asian countries seems to be lower than the Western countries but, it has increased recently due to the rise of obesity, type 2 diabetes and MS in this region. One of the main reasons for the increase in obesity, diabetes and MS in Asia is a lifestyle change and industrialization. Today, NAFLD is recognized as a major chronic liver disease in Asia. Therefore, prevention of this disease in Asian countries is very important and the best strategy for prevention and control of NAFLD is lifestyle modifications. Lifestyle modification programs are typically designed to change bad eating habits and increase physical activity that is associated with clinically significant improvements in obesity, type 2 diabetes and MS. CONCLUSION: Prevention of NAFLD is very important in Asian countries particularly in Arab countries because of high prevalence of obesity, diabetes and MS